Unknown

Dataset Information

0

Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trials.


ABSTRACT: Background Patients with metastatic colorectal cancer (mCRC) who progress on standard therapies may be eligible for phase I trials. To better delineate the risk-benefit ratio, we assessed toxicities, clinical outcomes and prognostic factors. Methods Records of mCRC patients on phase I trials at our institution over 18 years were reviewed. Univariable (UVA) and multivariable analyses (MVA) were undertaken and a prognostic model developed. Results There were 187 enrollments on 37 phase I trials. Median age was: 59 (29-83) years and number of prior therapies: 3 (0-8). The clinical benefit rate (CBR): response (5.6%) + stable disease, was 43.1%. Median progression free survival (PFS) and overall survival (OS) was 7.7 weeks and 43.7 weeks, respectively. The MVA identified age > 60 years (HR 1.63, p < 0.004), albumin<3.5 g/dL (HR 3.69, p < 0.001), direct bilirubin>ULN (HR1.69, p < 0.01), and WBC ≥ 5.2 k/uL (HR 1.97, p < 0.001) as negative prognostic factors. A risk score based on the MVA revealed that patients with a score of 0-1 had an improved OS (58.7 weeks) compared to a score of 2 (49.9 weeks, p < 0.01) and 3 (14.1 weeks, p < 0.001). Conclusions Phase 1 trials may offer similar or better clinical outcome for mCRC patients than standard third line therapies; the prognostic model could assist in selecting appropriate patients.

SUBMITTER: Kam AE 

PROVIDER: S-EPMC6461536 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trials.

Kam Audrey E AE   Pendurti Gopichand G   Shah Umang H UH   Ghalib Mohammad H MH   Chaudhary Imran I   Chuy Jennifer J   Rajdev Lakshmi L   Kaubisch Andreas A   Aparo Santiago S   Mantzaris Ioannis I   Goel Sanjay S  

Investigational new drugs 20181012 3


Background Patients with metastatic colorectal cancer (mCRC) who progress on standard therapies may be eligible for phase I trials. To better delineate the risk-benefit ratio, we assessed toxicities, clinical outcomes and prognostic factors. Methods Records of mCRC patients on phase I trials at our institution over 18 years were reviewed. Univariable (UVA) and multivariable analyses (MVA) were undertaken and a prognostic model developed. Results There were 187 enrollments on 37 phase I trials. M  ...[more]

Similar Datasets

| S-EPMC8421910 | biostudies-literature
| S-EPMC3364990 | biostudies-literature
| S-EPMC11458866 | biostudies-literature
| S-EPMC3642113 | biostudies-literature
| S-EPMC9077106 | biostudies-literature
| S-EPMC9016295 | biostudies-literature
| S-EPMC6729005 | biostudies-literature
| S-EPMC11430869 | biostudies-literature
| S-EPMC8814658 | biostudies-literature
| S-EPMC5504309 | biostudies-literature